Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials. The present studies mechanistically extended our initial observations. Low doses of sorafenib and vorinosta...

詳細記述

保存先:
書誌詳細
主要な著者: Park, Margaret A., Zhang, Guo, Martin, Aditi Pandya, Hamed, Hossein, Mitchell, Clint, Hylemon, Philip B., Graf, Martin, Rahmani, Mohamed, Ryan, Kevin, Liu, Xiang, Spiegel, Sarah, Norris, James, Fisher, Paul B., Grant, Steven, Dent, Paul
フォーマット: Artigo
言語:Inglês
出版事項: 2008
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2674577/
https://ncbi.nlm.nih.gov/pubmed/18787411
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料